LeadsBiolabs-B_Providing professional financial news and data related to LeadsBiolabs-B, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

LeadsBiolabs-B (09887.HK): LBL-024 (Opatisumab) Receives CDE IND Approval for Metastatic Colorectal Cancer; IO 2.0 Portfolio Expands to Gastrointestinal Tumors

Tags：

LeadsBiolabs-B 09887.HK

2026-08-03

ETF
Csop Hang Seng Index Daily (2x) Leveraged Product (07200.HK) Slides 0.25% in Morning Session, Turnover Reaches HK$127 Million
ETF
Value Gold ETF (03081.HK) Dips 0.31% in Morning Session, Total Asset Size Hits HK$4.14 Billion
ETF
ChinaAMC Asia High Dividend ETF (03145.HK) Edges Up 0.07% in Morning Session, NAV Per Unit Stands at HK$14.641
ETF
Csop Ftse Hk-Korea Tech+ Index Etf (03431.HK) Edges Up 0.15% in Morning Session at HK$9.895
ETF
ChinaAMC HSI ESG ETF(03403.HK) Rises 0.30% in Morning Session with Average Trading Price at HK$53.64
ETF
iShares Core S&P Bse Sensex India Index ETF(02836.HK) Edges Up 0.90% in Morning Session, Total Asset Size Reaches HK$4.697 Billion
ETF
CSOP Hang Seng TECH Index Daily (2x) Leveraged Product(07226.HK) Rises 1.50% in Morning Session, Turnover Hits HK$258 Million
ETF
Csop Nikkei 225 Daily (-2x) Inverse Product(07515.HK) Rises 5.67% in Morning Session at HK$15.48
Finance
BExcellent Group Holdings Limited(01775.HK): Appointment of Mr. Wu Jingheng as Executive Director
Finance
SDMC Technology (00901.HK): Revenue Projected to Rise 30%-40% and Net Profit to Grow 70%-80% in First Half

Scan QR Code

Download App